Evidence map›Paper›PMID 32730293›Full record

ArticlePloS one2020

The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms.

Jian Cui, Zhipeng Qu, Yuka Harata-Lee, Hanyuan Shen, Thazin Nwe Aung, Wei Wang, R Daniel Kortschak, David L Adelson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jian CuiDepartment of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.
Zhipeng QuDepartment of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.
Yuka Harata-LeeDepartment of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.ORCID 0000-0002-5850-2471
Hanyuan ShenDepartment of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.
Thazin Nwe AungDepartment of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.
Wei WangZhendong Research Institute, Shanxi-Zhendong Pharmaceutical Co Ltd, Beijing, China.
R Daniel KortschakDepartment of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.
David L AdelsonDepartment of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia.ORCID 0000-0003-2404-5636
The University of Adelaide · AUShanxi Zhendong Pharmaceutical (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditional Chinese Medicine (TCM) preparations are often extracts of single or multiple herbs containing hundreds of compounds, and hence it has been difficult to study their mechanisms of action. Compound Kushen Injection (CKI) is a complex mixture of compounds extracted from two medicinal plants and has been used in Chinese hospitals to treat cancer for over twenty years. To demonstrate that a systematic analysis of molecular changes resulting from complex mixtures of bioactives from TCM can identify a core set of differentially expressed (DE) genes and a reproducible set of candidate pathways. We used in vitro cancer models to measure the effect of CKI on cell cycle phases and apoptosis, and correlated those phenotypes with CKI induced changes in gene expression. We treated two cancer cell lines with or without CKI and assessed the resulting phenotypes by employing cell viability and proliferation assays. Based on these results, we carried out high-throughput transcriptome data analysis to identify genes and candidate pathways perturbed by CKI. We integrated these differential gene expression results with previously reported results and carried out validation of selected differentially expressed genes. CKI induced cell-cycle arrest and apoptosis in the cancer cell lines tested. In these cells CKI also altered the expression of 363 core candidate genes associated with cell cycle, apoptosis, DNA replication/repair, and various cancer pathways. Of these, 7 are clinically relevant to cancer diagnosis or therapy, 14 are cell cycle regulators, and most of these 21 candidates are downregulated by CKI. Comparison of our core candidate genes to a database of plant medicinal compounds and their effects on gene expression identified one-to-one, one-to-many and many-to-many regulatory relationships between compounds in CKI and DE genes. By identifying genes and promising candidate pathways associated with CKI treatment based on our transcriptome-based analysis, we have shown that this approach is useful for the systematic analysis of molecular changes resulting from complex mixtures of bioactives.

Indexed as

InjectionsApoptosisCell CycleCell Line, TumorDrugs, Chinese HerbalGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMolecular Sequence AnnotationNeoplasmsReproducibility of ResultsDrugs, Chinese Herbalkushen

Identifiers

PMID32730293
PMCPMC7392229
OpenAlexW3047575652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.